# OnCo record paper-psmaddition-lancet-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-psmaddition-lancet-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-psmaddition-lancet-2026" ;
  schema:name "[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial"@en ;
  schema:description "Published report from the PSMAddition trial registered as NCT04720157, in The Lancet (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-psmaddition-lancet-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(26)01092-5>, <https://pubmed.ncbi.nlm.nih.gov/42561994/>, <https://europepmc.org/article/MED/42561994>, <https://clinicaltrials.gov/study/NCT04720157> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(26)01092-5> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Tagawa ST, Sartor O, Piulats JM, et al." ;
  onco:trials <https://onco.cc/trials/psmaddition/> ;
  onco:journals <https://onco.cc/journals/lancet/> .